July 30, 2019
Rose
The "pay for delay" agreements involve one company paying other drugmakers to refrain from producing a generic version after the drug’s patent expires. The practices caused consumers "to pay as much as 90% more for drugs shielded from competition," state Attorney General Xavier Becerra's office said. Four settlements were reached with drug companies Teva Pharmaceutical Industries, Endo Pharmaceuticals and Teikoku Pharma. Meanwhile, Pfizer confirms its reported plans to absorb Mylan.
from Kaiser Health News https://ift.tt/2ZmKXnE
July 30, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Even When Not In Rome, Eat A Mediterranean Diet To Cut Heart Disease Risk- Must-Reads Of The Week On Health Care
- State Highlights: Ohio’s Infant Mortality Rate Drops Overall, But Rate For Black Babies Increases; Family Planning Services Cut At Milwaukee Clinic
- Child-Friendly Prison Visits Help Moms In Washington Stay Connected, Reduce Trauma Of Separation
- Viewpoints: Trump Is Still Focused On Taking Away Health Care; Keep Up The Fight Against Protections For Preexisting Conditions
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment